BioSpace News Archive

Caresyntax, a pioneer in surgical automation, analytics, and AI software and technologies, and the Association of periOperative Registered Nurses have partnered to launch a performance guarantee program for their operational analytics solution to make operating rooms more efficient.

Perseus Holdings USA, an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer, today announced the appointment of Dr. Mark Corrigan, an accomplished biotechnology executive

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Gaurav Vij as the Company’s head of business development

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that further validate the superiority of DTM™ Spinal Cord Stimulation (SCS) in providing back pain relief, compared with conventional SCS therapy, using the Medtronic Intellis

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Katena Products (“Katena”), a leading global provider of precision ophthalmic instruments, biologics, and devices to hospitals, surgical centers, and ophthalmic and optometric offices announces the purchase of Micro-Select Instruments Inc.(“Micro-Select”). Micro-Select was founded in 2005 by Lenny Moll and Mike Dorenkamp and is located in St. Clair, MO. The business specializes in manufacturing high precision ophth

Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $12.00 per share

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2020 before the US financial markets open on October 29, 2020.

Sarissa Capital Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 17,500,000 units, at a price of $10.00 per unit. The Company’s sponsor, Sarissa Capital Acquisition Sponsor LLC (the “Sponsor”), was capitalized by investment funds managed by Sarissa Capital Management LP , which was

Masimo (NASDAQ: MASI) will release third quarter 2020 financial results for the period ended September 26, 2020, after the market closes on Tuesday, October 27, 2020. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive V